Eureka Therapeutics
Signal active
Organization
Contact Information
Overview
Eureka Therapeutics is a biotechnology company that focuses on immunotherapies for the treatment of cancer. They have developed E-ALPHA into one of the world’s largest human-derived antibody phage libraries to generate target-specific antibodies, including T cell receptor-mimic antibodies against intracellular targets.
About
Industries
Biotechnology, Health Care, Medical, Therapeutics
Founded
2006
Employees
11-50
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Eureka Therapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical, Therapeutics sector. The company focuses on Biotechnology and has secured $15.6B in funding across 112 round(s). With a team of 11-50 employees, Eureka Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series C - Eureka Therapeutics, raised $21.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
7
Investors
5
Lead Investors
0
Total Funding Amount
$139.5M
Details
6
Eureka Therapeutics has raised a total of $139.5M in funding over 6 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2007 | Seed | 1.4K | ||
| 2007 | Early Stage Venture | 1.2M | ||
| 2008 | Early Stage Venture | 1.7M | ||
| 2014 | Late Stage Venture | 21.0M |
Investors
Eureka Therapeutics is funded by 18 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Acorn Campus Ventures | - | FUNDING ROUND - Acorn Campus Ventures | 21.0M |
| Suma Venture | - | FUNDING ROUND - Suma Venture | 21.0M |
| Eureka Therapeutics | - | FUNDING ROUND - Eureka Therapeutics | 21.0M |
| Harbinger Ventures | - | FUNDING ROUND - Harbinger Ventures | 21.0M |
Recent Activity
There is no recent news or activity for this profile.